Sign in
Knowstox

Fundamentals snapshot

Monte Rosa Therapeutics, Inc.

GLUE · NMS · Healthcare · Biotechnology

Current price

$10.52

52-week range

$8.94 - $25.77

Market cap

$897.50M

One-glance verdict

Undervalued

$19.92 our estimate vs market $10.52

Wall Street consensus: $26.88 (34.9% higher than our fair-value estimate)

Balance sheet

Healthy

-4.19x Concerning

Net cash $583.12M. Interest coverage shows how many times profit covers the interest bill.

What this company does

Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics is developing new medicines that use the body's own ways to break down disease-causing proteins, aiming to treat serious illnesses like cancer and autoimmune diseases. Their main income will eventually come from selling these medicines, and their success matters because they are working on treatments for conditions with few good options.

Price history

How the share price has moved

—
Loading price history…

Earnings history

Last 8 quarters — what happened

Click any quarter to read the call summary and what the numbers say.

Free cash flow by quarter (oldest to newest)
FY2024 Q3 $-21.39M FY2024 Q4 $128.74M FY2025 Q1 $-47.08M FY2025 Q2 $-36.41M FY2025 Q3 $99.78M FY2025 Q4 $-43.78M FY2026 Q1 $-39.24M FY2026 Q2 $-48.84M
Revenue —
Net income $-43.40M
Diluted EPS —
Operating cash flow $-44.11M
Free cash flow $-48.84M
Revenue —
Net income $-44.50M
Diluted EPS —
Operating cash flow $-37.37M
Free cash flow $-39.24M
Revenue —
Net income $-38.60M
Diluted EPS —
Operating cash flow $-43.01M
Free cash flow $-43.78M
Revenue —
Net income $-27.08M
Diluted EPS —
Operating cash flow $100.43M
Free cash flow $99.78M
Revenue —
Net income $-12.29M
Diluted EPS —
Operating cash flow $-34.72M
Free cash flow $-36.41M
Revenue —
Net income $46.88M
Diluted EPS —
Operating cash flow $-45.49M
Free cash flow $-47.08M
Revenue —
Net income $13.44M
Diluted EPS —
Operating cash flow $128.92M
Free cash flow $128.74M
Revenue —
Net income $-23.86M
Diluted EPS —
Operating cash flow $-20.99M
Free cash flow $-21.39M

Is it cheap or expensive?

Fair value $19.92 vs current price $10.52

Wall Street consensus is the average analyst price target: $26.88 (34.9% higher than our fair-value estimate).

Our most-likely fair value is $19.92 a share — about 89.4% above today's price of $10.52, so the stock currently looks cheap (undervalued).

undervalued

We estimate the cash this business should generate over the next 10 years and beyond, then convert it to today's money for a fair value per share, in its trading currency. Cautious, middle and optimistic growth cases give a range. Not for banks/insurers.

Base

Growth 15.0% · Discount 9.8% · Terminal 3.0%

$19.92

Bear

Growth 5.0% · Discount 9.8% · Terminal 3.0%

$14.39

Bull

Growth 25.0% · Discount 9.8% · Terminal 3.0%

$29.05

Is it drowning in debt?

Healthy

Net cash $583.1M - more cash than debt. Interest coverage -4.2x.

Net debt $-583.12M
Interest coverage -4.19x

Monte Rosa Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.

Healthy
Worse cushion Baseline Better cushion
GLUE BASELINE Monte Rosa Therapeutics, Inc.

Total debt $37.99M Interest coverage -4.19x This is the baseline the peer rows are being compared against.

-4.19x
PBLS Parabilis Medicines, Inc.

Total debt $47.51M Interest coverage -99.92x Neither company has much profit cushion over interest right now.

-99.92x
ACAD Acadia Pharmaceuticals Inc.

Total debt $73.85M Interest coverage 3.30x This peer still has a real interest-payment cushion, while GLUE does not.

3.30x
CELC Celcuity Inc.

Total debt $754.39M Interest coverage -10.04x Neither company has much profit cushion over interest right now.

-10.04x
CDNA CareDx, Inc.

Total debt $19.25M Interest coverage -2.73x Neither company has much profit cushion over interest right now.

-2.73x

What you should know

The case for and against GLUE

2 Rewards 2 Risks

Rewards

  • Revenue grew 63.5% last year.
  • Free cash flow was positive in 1/10 years.

Risks

  • Return on equity was -42.7% last year — the company lost money on shareholders' equity.
  • Insider ownership is only 0.6% (peer median: 3.1%).

The numbers

All the key metrics, grouped by purpose

Tap any ? icon to learn what it means.

Valuation

How expensive the stock looks

P/E (TTM)
—
Forward P/E
-5.70x
P/B
1.84x
P/S
31.24x
EV/EBITDA
-1.81x
PEG ratio
—

Profitability

How much profit each dollar creates

Gross margin
0.0%
Operating margin
-547.8%
Net margin
0.0%
ROE
-42.7%
ROA
-21.6%

Health

Liquidity and balance-sheet strength

Debt / equity
0.08x
Current ratio
10.58x
Quick ratio
10.49x
Total debt
$37.99M
Total cash
$621.10M

Growth

How the business has been compounding

Revenue TTM
$28.73M
Revenue 5Y CAGR
—
EPS TTM
-1.75
EPS 5Y CAGR
—

Cash flow

How much cash the business throws off

Operating CF TTM
$-24.07M
Free CF TTM
$-27.50M
FCF margin
-95.7%

Dividend

Shareholder payout

Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—